Norinchukin Bank The increased its stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 9.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,293 shares of the financial services provider's stock after purchasing an additional 1,431 shares during the period. Norinchukin Bank The's holdings in CME Group were worth $3,784,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CME. SJS Investment Consulting Inc. grew its stake in CME Group by 570.6% during the 4th quarter. SJS Investment Consulting Inc. now owns 114 shares of the financial services provider's stock valued at $26,000 after acquiring an additional 97 shares in the last quarter. New Age Alpha Advisors LLC grew its position in shares of CME Group by 50.0% in the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock valued at $30,000 after purchasing an additional 43 shares in the last quarter. Financial Life Planners purchased a new stake in shares of CME Group in the fourth quarter valued at approximately $32,000. Knuff & Co LLC acquired a new stake in shares of CME Group in the fourth quarter valued at approximately $33,000. Finally, Fortitude Family Office LLC lifted its position in CME Group by 120.3% during the fourth quarter. Fortitude Family Office LLC now owns 152 shares of the financial services provider's stock worth $35,000 after buying an additional 83 shares in the last quarter. 87.75% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, Director Howard J. Siegel sold 10,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $260.00, for a total value of $2,600,000.00. Following the completion of the sale, the director now directly owns 21,873 shares of the company's stock, valued at $5,686,980. The trade was a 31.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Julie Winkler sold 11,592 shares of CME Group stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $249.17, for a total value of $2,888,378.64. Following the sale, the insider now owns 21,885 shares in the company, valued at $5,453,085.45. This trade represents a 34.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,076 shares of company stock worth $6,871,496 over the last 90 days. 0.30% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
CME has been the subject of a number of recent research reports. Oppenheimer raised their target price on CME Group from $269.00 to $279.00 and gave the stock an "outperform" rating in a research note on Friday, April 11th. Piper Sandler boosted their target price on shares of CME Group from $275.00 to $283.00 and gave the company an "overweight" rating in a report on Tuesday, April 8th. Citigroup cut shares of CME Group from a "buy" rating to a "neutral" rating and dropped their price target for the company from $255.00 to $250.00 in a research note on Monday, January 6th. Bank of America lifted their price target on shares of CME Group from $200.00 to $219.00 and gave the company an "underperform" rating in a research report on Wednesday, April 2nd. Finally, Keefe, Bruyette & Woods increased their price objective on CME Group from $256.00 to $257.00 and gave the stock a "market perform" rating in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $247.73.
Get Our Latest Stock Report on CME
CME Group Stock Down 1.5 %
Shares of CME stock traded down $4.08 during trading on Wednesday, reaching $261.48. The company's stock had a trading volume of 3,475,218 shares, compared to its average volume of 2,155,814. The company has a market capitalization of $94.23 billion, a price-to-earnings ratio of 27.04, a P/E/G ratio of 6.76 and a beta of 0.43. CME Group Inc. has a 1-year low of $190.70 and a 1-year high of $273.42. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.02. The stock's 50-day moving average price is $257.73 and its 200 day moving average price is $241.07.
CME Group (NASDAQ:CME - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. CME Group had a return on equity of 13.62% and a net margin of 57.52%. The business had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. On average, research analysts anticipate that CME Group Inc. will post 10.49 EPS for the current year.
CME Group Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, March 26th. Investors of record on Friday, March 7th were issued a $1.25 dividend. This is a boost from CME Group's previous quarterly dividend of $1.15. The ex-dividend date of this dividend was Friday, March 7th. This represents a $5.00 annualized dividend and a yield of 1.91%. CME Group's dividend payout ratio (DPR) is 51.71%.
CME Group Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Further Reading

Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.